Claisse Guillaume, Absi Lena, Cognasse Fabrice, Alamartine Eric, Mariat Christophe, Maillard Nicolas
Service de Néphrologie et Transplantation Rénale, Hôpital NORD, CHU de Saint-Etienne, Université Jean MONNET, 42055 Saint-Etienne cedex 02, France.
Laboratoire d'Immunologie, EFS Loire-Auvergne, 25 Boulevard Pasteur, 42100 Saint-Etienne, France.
Hum Immunol. 2017 Apr;78(4):336-341. doi: 10.1016/j.humimm.2017.02.003. Epub 2017 Feb 9.
Complement-binding assays are proposed to better stratify the risk of antibody-mediated rejection associated-graft failure. Despite promising clinical results, some have suggested that the MFI of anti-HLA antibodies may influence these tests.
We investigated the impact of Abs MFI reduction, induced by plasmapheresis, on C1q- and C3d-binding assays. Sera provided from 7 sensitized kidney transplant patients were analyzed.
Four hundreds and thirty-three SABs were analyzed. Before plasmapheresis, when compared to C1q- SABs, C1q+ SABs had a higher median MFI [17397 (IQR: 14851-18794) vs. 2745 (IQR: 1125-6476), p<0.01]. SABs that remained C1q+ after plasmapheresis had a higher median MFI. Regarding the C3d assay, results were strictly comparable. MFI value was a powerful predictor of both C1q and C3d positivity [AUC 0.97 (CI95% 0.95-0.99) and 0.96, (CI95% 0.93-0.98), respectively].
Our data suggest that both C1q- and C3d-binding assays are intimately linked to the MFI of anti-HLA Abs.
补体结合试验旨在更好地对抗体介导的排斥反应相关移植失败的风险进行分层。尽管临床结果令人鼓舞,但一些人认为抗 HLA 抗体的平均荧光强度(MFI)可能会影响这些检测。
我们研究了血浆置换诱导的抗体 MFI 降低对 C1q 和 C3d 结合试验的影响。分析了 7 名致敏肾移植患者提供的血清。
共分析了 433 份特异性抗体(SABs)。在血浆置换前,与 C1q 阴性 SABs 相比,C1q 阳性 SABs 的中位 MFI 更高[17397(四分位间距:14851 - 18794)对 2745(四分位间距:1125 - 6476),p<0.01]。血浆置换后仍为 C1q 阳性的 SABs 具有更高的中位 MFI。关于 C3d 试验,结果具有严格的可比性。MFI 值是 C1q 和 C3d 阳性的有力预测指标[曲线下面积(AUC)分别为 0.97(95%置信区间 0.95 - 0.99)和 0.96(95%置信区间 0.93 - 0.98)]。
我们的数据表明,C1q 和 C3d 结合试验均与抗 HLA 抗体的 MFI 密切相关。